RxDoctor Payments DataLook up a doctor →

Sanjay Aggarwal, MD

Internal Medicine · New Haven, CTNPI 1912927658

Payments from drug & device makers

$58,165in general payments, 2019–2025

Across 613 payments — averaging $94.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kadmon Corporation LLC$40K
  • Sanofi US Services Inc.$5K
  • AbbVie$2K
  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • plus $7K from 40 others

What the payments were for

  • Consulting fees$39,90074%
  • Food & beverage$13,64625%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,165 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$58,360
Medicare patients
135
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$20,258
OzempicSemaglutide16$17,899
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl72$11,723
FarxigaDapagliflozin Propanediol25$11,495
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,244
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$9,908
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$6,881
SantylCollagenase Clostridium Hist.18$6,059
MyrbetriqMirabegron22$5,737
XareltoRivaroxaban19$5,327
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,383
Lidocaine23$2,248
Midodrine Hcl13$2,247
Atorvastatin Calcium121$1,667
Mirtazapine37$1,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$616$20,25856 claims
Novo NordiskOzempic$516$17,89916 claims
GSKTrelegy Ellipta, Shingrix$1,713$13,62826 claims
AstraZenecaFarxiga$1,969$11,49525 claims
Orexo US, Inc.Zubsolv$225$9,90812 claims
Indivior Inc.Suboxone$615$6,88113 claims
Astellas Pharma US IncMyrbetriq$192$5,73722 claims
Johnson & JohnsonXarelto$67$5,32719 claims
Almatica Pharma LLCSertraline Hcl$19$44037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →